Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFocusrite Regulatory News (TUNE)

Share Price Information for Focusrite (TUNE)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £114.69m
TUNE Live PriceLast checked at - London Stock Exchange

Intraday Focusrite Share Chart

Issue of Management Options - Replacement

11 Jul 2022 08:00

RNS Number : 9249R
Focusrite PLC
11 July 2022
Β 

For immediate release

Β 

An amendment has been made to the RNS announcement number 7133P released on 22 June 2022 at 07:00.

The following correction has been made to Sally McKone's total shareholding in the third paragraph.Β 

The text now reads: "Following the award, Ms McKone will have a beneficial holding of 5,678 shares shares, being 0.01% of the issued ordinary share capital of the Company."

All other details remain unchanged. The full amended text is show below.

Β 

Β 

Β 

Issue of Management Shares

FOCUSRITE PLC

Released 07:00:07Β 22 June 2022

Β 

RNS Number : 7133P

Focusrite PLC

22 June 2022

Β 

Β 

Focusrite plc

("the Company" orΒ "the Group")

Issue of Management Shares

Focusrite plc (AIM: TUNE), the global music and audio products company supplying hardware and software used by professional and amateur musicians and the entertainment industry, announces the issue of the second tranche of 4,029 management share awards to Sally McKone, the Company's Chief Financial Officer. As set out in the Company's announcement of 18 May 2021, such awards were made as compensation for certain incentive arrangements which she forfeited or was otherwise not awarded on leaving her former employer to join the Group.

The shares, to be issued from the Company's Employee Benefit Trust were determined by the Company's Remuneration Committee and approved by the Board.

The Company will cash settle the resulting tax and National Insurance elements. Accordingly, Ms McKone will be awarded a net holding of 2,136 shares. Following the award, Ms McKone will have a beneficial holding of 5,678 shares, being 0.01% of the issued ordinary share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1

DetailsΒ of the persons discharging managerial responsibilitiesΒ IΒ person closelyΒ associated

a)

Name

Sally McKone

2

ReasonΒ forΒ theΒ notification

a)

Position/status

Β ChiefΒ FinancialΒ Officer

b)

InitialΒ notificationΒ /Amendment

Β Initial notification

3

Details of the issuer,Β emissionΒ allowance marketΒ participant,Β auctionΒ platform,Β auctioneerΒ orΒ auction monitor

a)

Name

Focusrite plc

b)

LEI

213800JJ51KA4LOTF736

4A

DetailsΒ ofΒ theΒ transaction(s):Β sectionΒ toΒ beΒ repeated forΒ (i)Β eachΒ typeΒ of instrument;Β (ii)Β eachΒ typeΒ ofΒ transaction;Β (iii)Β eachΒ date;Β andΒ (iv)Β eachΒ place whereΒ transactions haveΒ beenΒ conducted

a)

DescriptionΒ of the financialΒ instrument,Β typeΒ of instrument

Ordinary Shares of 0.1p each in Focusrite plc

IdentificationΒ code

GB00BSBMW716

b)

NatureΒ ofΒ theΒ transaction

Issue of sharesΒ ordinary sharesΒ from EBTΒ of 0.1p each in Focusrite plc.

c)

Price(s)Β andΒ volume(s)

Β 

Price(s)

Volumes

Nil cost

4,029Β (settled in part by the transfer ofΒ 2,136Β ordinary shares and in part with a cash payment equal to market value ofΒ 1,893Β ordinary shares to meetΒ the PDMR'sΒ liability to income tax and employee national insurance arising on the issue ofΒ 4,029Β shares)

d)

Aggregated information

- Aggregated volumeΒ 

- PriceΒ 

Not applicable - single transaction

e)

Date of the transaction

20 June 2022

f)

Place of the transaction

Outside a trading venue

Β 

Β 

- Ends -

Enquiries:

Focusrite plc +44 (0) 149 446 2246

Tim Carroll, Chief Executive Officer

Sally McKone, Chief Financial Officer

Investec Bank plc (Nominated Adviser and Joint Broker) +44 (0) 20 7597 5970

David Flin

William Brinkley

Charlotte Young

Peel Hunt LLP (Joint Broker) +44 (0) 20 7418 8900

Edward Knight

Michael Burke

James Smith

Belvedere Communications +44 (0) 20 3687 2756

John West

Llew Angus

Β 

Notes to Editors

Focusrite plc is a global audio products group that develops and markets proprietary hardware and software products. Used by audio professionals and musicians, its solutions facilitate the high-quality production of recorded and live sound. The Focusrite Group trades under nine established brands: Focusrite, Focusrite Pro, Novation, Ampify, ADAM Audio, Martin Audio, Optimal Audio, Linea and Sequential.

With a high-quality reputation and a rich heritage spanning decades, its brands are category leaders in the music-making and audio recording industries. Focusrite and Focusrite Pro offer audio interfaces and other products for recording musicians, producers, and professional audio facilities. Novation and Ampify products are used in the creation of electronic music, from synthesisers and grooveboxes to industry-shaping controllers and inspirational music-making apps. ADAM Audio studio monitors have earned a worldwide reputation based on technological innovation in the field of studio loudspeaker technology. Martin Audio designs and manufactures performance-ready systems across the spectrum of sound reinforcement applications. Linea designs, develops, manufactures and sells market innovative professional audio equipment globally. Sequential designs and manufactures high end analogue synthesizers.Β 

The Focusrite Group has offices in four continents and a global customer base with a distribution network covering approximately 240 territories.

Focusrite plc is traded on the AIM market, London Stock Exchange.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactΒ rns@lseg.comΒ or visitΒ www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see ourΒ Privacy Policy.

Β 

END

Β 

Β 

DSHEAFKFAEKAEAA

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHQKLFBLDLZBBL
Date   Source Headline
27th May 20267:00 amRNSNotice of Results
5th May 20264:25 pmRNSTR-1
8th Apr 20263:56 pmRNSTR-1
19th Mar 20267:00 amRNSTrading Update: Trading in-line with expectations
2nd Mar 20267:00 amRNSBoard Changes
24th Dec 20259:21 amRNSTR-1
24th Dec 20259:21 amRNSTR-1
24th Dec 20259:19 amRNSTransfer of shares to Trust
24th Dec 20259:19 amRNSTransfer of shares to Trust
18th Nov 202512:38 pmRNSDirector Share Dealings
4th Nov 20257:00 amRNSInterim Results
14th Oct 20257:00 amRNSNotice of Results
16th Sep 20257:00 amRNSTrading Update
7th May 20253:25 pmRNSTR-1
30th Apr 20253:41 pmRNSDividend Timetable Correction
29th Apr 20257:00 amRNSInterim Results
16th Apr 20252:38 pmRNSGrant of Share Options to PDMRs
11th Apr 20258:50 amRNSTR-1
8th Apr 20251:43 pmRNSTR-1
8th Apr 20257:00 amRNSTR-1
8th Apr 20257:00 amRNSTR-1
3rd Apr 20257:00 amRNSNotice of Interim Results
26th Mar 20253:16 pmRNSTR-1
20th Mar 20257:00 amRNSTrading Update
19th Mar 20258:13 amRNSTR-1
4th Mar 20252:46 pmRNSTR-1
31st Jan 202512:29 pmRNSResult of AGM
31st Jan 20257:00 amRNSAGM Statement and Trading Update
11th Dec 20247:00 amRNSTR-1
5th Dec 20243:38 pmRNSDirector Share Dealings
5th Dec 20243:37 pmRNSGrant of Share Options to PDMRs
5th Dec 20247:00 amRNSTR1
27th Nov 20247:00 amRNSFinal Results for the Year Ended 31 Aug 2024
30th Oct 20247:00 amRNSNotice: Final Results, Change of Year End, Auditor
28th Aug 20247:00 amRNSTrading Statement
1st Aug 20247:00 amRNSTR-1
15th Jul 20244:17 pmRNSTR-1
25th Apr 20247:00 amRNSInterim Results
22nd Apr 20246:09 pmRNSTR-1
9th Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20247:00 amRNSNotice of Interim Results
22nd Mar 20243:36 pmRNSNotification of PDMR Transactions
22nd Mar 20248:01 amRNSTR-1
20th Mar 20247:01 amRNSTR-1
19th Mar 20244:44 pmRNSNotification of PDMR Transactions
18th Mar 20247:00 amRNSTrading Update
14th Feb 20243:10 pmRNSNotification of PDMR Transactions
7th Feb 20242:25 pmRNSTR-1
19th Jan 202412:59 pmRNSResult of AGM
19th Jan 20247:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.